<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Unsafe abortion</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Unsafe abortion</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Unsafe abortion</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadia Haider, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Laura Laursen, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jody Steinauer, MD, MAS, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 26, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H18736521"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Access to safe abortion care is an essential component of comprehensive health care. In settings where abortion is restricted, patients access abortion outside of the formal healthcare system; this may be performed by an untrained clinician or be self-managed (self-managed abortion; SMA). SMA can be performed "safely" (usually through the internet with self-procured <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> and <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>) or "unsafely" (often with herbal preparations, self-inflicted trauma or uterine instrumentation, or toxic substances).</p><p>Safe abortion (typically performed with a combination of <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> and <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>, though other regimens may be used) is associated with few adverse events and the overall death rate from safe abortion is far less than the maternal mortality rate among live births in the United States. By contrast, unsafe abortion is associated with high morbidity and mortality. </p><p>Unsafe abortion is presented here. Safe abortion, including first- and second-trimester medication and procedural pregnancy termination, as well as septic abortion, are presented separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3313.html" rel="external">"Overview of pregnancy termination"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3296.html" rel="external">"First-trimester pregnancy termination: Medication abortion"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3287.html" rel="external">"First-trimester pregnancy termination: Uterine aspiration"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14194.html" rel="external">"Overview of second-trimester pregnancy termination"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/130878.html" rel="external">"Septic abortion: Clinical presentation and management"</a>.)</p><p></p><p class="headingAnchor" id="H31293276"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>The World Health Organization (WHO) defines "safe" abortion as abortion in countries where abortion law is not restrictive (ie, abortion is legally permitted for social or economic reasons, or without specification as to reason) or countries in which, despite restrictions, safe abortion is broadly available [<a href="#rid1">1</a>]. </p><p>Conversely, "unsafe" abortion is performed by people lacking the necessary skills using a hazardous technique, and/or in an environment that does not meet minimum medical standards. Similar to WHO definitions, the Society of Family Planning (SFP) defines unsafe abortion as an abortion performed by an unskilled or untrained provider using unsafe (eg, ingesting toxic substances, abdominal trauma, intrauterine instrumentation) or less-studied (eg, herbal preparations, botanicals) methods to terminate a pregnancy [<a href="#rid2">2</a>]. (See <a class="local">'Methods of unsafe abortion'</a> below.)</p><p>The WHO has adopted a focus on safety to emphasize the procedure and its context rather than placing blame on the patients undergoing the procedure or emphasizing its legality [<a href="#rid3">3</a>]. </p><p class="headingAnchor" id="H31293283"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>It is estimated that 25 million unsafe abortions occur worldwide each year, and historically 97 percent of these abortions occur in resource-limited countries [<a href="#rid4">4</a>]. The incidence is lower in resource-rich countries where there is often better access to contraception, and medication and procedural abortion. In both resource-limited and resource-rich settings, those most vulnerable to undergoing unsafe abortions are individuals who are younger, poorer, and lack partner support [<a href="#rid5">5</a>].</p><p>Unsafe abortions also occur in countries with legal abortion. For example, in a 2011 cross-sectional study in the United States including 9500 people undergoing abortion, 1.4 percent reported they had used a substance other than <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> to self-induce abortion [<a href="#rid6">6</a>]. This number is expected to increase as abortion restrictions increase [<a href="#rid7">7,8</a>].</p><p class="headingAnchor" id="H3973155822"><span class="h1">METHODS OF UNSAFE ABORTION</span><span class="headingEndMark"> — </span>Safe methods for abortion are discussed separately. (See  <a class="medical medical_review" href="/d/html/3313.html" rel="external">"Overview of pregnancy termination"</a>.)</p><p>Unsafe, or less safe, methods may include [<a href="#rid7">7,9-12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral and injectable treatments</strong> – Oral and injectable treatments such as metal salts, phosphorus, lead, kerosene, turpentine, detergent solutions (eg, bleach), <a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">chloroquine</a>, hormones (eg, gynaecosid), and numerous teas and herbal remedies (eg, <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a>, parsley, Dong Quai, rose hips, gingerroot, chamomile, ruda [rue], Carachipita, arnica, bardana, sage, St. John's wort, black or blue cohosh, pennyroyal). </p><p></p><p class="bulletIndent1">Patients may also attempt to use large doses of oral contraceptive pills or analgesic medications [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1">In a study including 30 patients in the United States who self-induced their abortions with medications, the most common methods were <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a>, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, laxatives, oral contraceptives, hormonal injections, and unspecified pills (not <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>) or injections [<a href="#rid14">14</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preparations placed in the cervix, vagina, or rectum </strong>– Such preparations may include potassium permanganate tablets, herbal preparations, detergents, and enemas.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intrauterine instrumentation</strong> – Intrauterine instrumentation may include catheter insertion followed by infusion of alcohol, <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, or other solution, or insertion of foreign bodies. Penetration with sharp objects (eg, coat hanger, knitting needle) with potential for uterine perforation and use of unclean instruments (eg, unsterilized catheters) are methods that pose the highest risks for morbidity and mortality [<a href="#rid9">9</a>]. </p><p></p><p class="bulletIndent1">Transcervical introduction of compounds such as mixtures of soap, cresol, and phenol can cause renal toxicity, cardiac toxicity, and death [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trauma to the abdomen</strong> – Trauma may include self-inflicted blows to the abdomen, abdominal massage, jumping from an unsafe height, and lifting heavy weights. Traditional practitioners commonly use vigorous abdominal massage with the idea that this will result in disruption of the pregnancy; this has resulted in uterine rupture and other morbidity [<a href="#rid16">16</a>].</p><p></p><p>In one qualitative study including 14 individuals that attempted self-managed abortion (SMA) in the United States, approximately half used herbal substances; others used prescription or over-the-counter medications, and one attempted intrauterine instrumentation [<a href="#rid17">17</a>]. None used <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> or <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>.</p><p class="headingAnchor" id="H541559363"><span class="h1">MORBIDITY AND MORTALITY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Morbidity</strong> – In resource-limited countries in 2015, it was estimated that seven million females (estimated rate of 6.9 per 1000) were treated for complications related to unsafe abortion [<a href="#rid18">18,19</a>]. </p><p></p><p class="bulletIndent1">In a systematic review of 43 studies evaluating patients hospitalized with abortion-related complications in areas where most abortions are unsafe (14 countries in Africa, six countries in Asia, four countries in Latin America), the type and median prevalence of complications were [<a href="#rid20">20</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemorrhage – Severe 3 percent, nonsevere or unspecified 44.2 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Anemia – 38.1 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Infection – Severe 5.1 percent, nonsevere or unspecified 24 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Trauma – Severe 7.2 percent, nonsevere or unspecified 5.5 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Renal failure – 1.6 percent</p><p></p><p class="bulletIndent1">Most patients had more than one complication. Such complications may lead to death or other long-term sequelae (eg, infertility). </p><p></p><p class="bulletIndent1">Factors that increase morbidity at the time of unsafe abortion include [<a href="#rid21">21</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lack of provider skill</p><p class="bulletIndent2"><span class="glyph">•</span>Poor technique</p><p class="bulletIndent2"><span class="glyph">•</span>Unsanitary conditions for performing the procedure</p><p class="bulletIndent2"><span class="glyph">•</span>Lack of appropriate equipment</p><p class="bulletIndent2"><span class="glyph">•</span>Use of toxic substances</p><p class="bulletIndent2"><span class="glyph">•</span>Poor maternal health</p><p class="bulletIndent2"><span class="glyph">•</span>Higher gestational age</p><p class="bulletIndent2"><span class="glyph">•</span>Lack of access to postabortion care</p><p></p><p class="bulletIndent1">In addition, social stigma, legal threats, and fear can prevent individuals who undergo unsafe abortion from accessing postabortion care, which is a critical aspect of reducing morbidity and saving lives.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mortality</strong> – Death due to unsafe abortion varies widely by setting and is subject to underreporting [<a href="#rid20">20,22</a>]. In resource-rich settings, it is estimated that 30 females die for every 100,000 unsafe abortions [<a href="#rid23">23</a>]. Mortality is higher in resource-limited settings (220 deaths per 100,000 unsafe abortions) and is even higher in certain regions (520 deaths per 100,000 unsafe abortions in sub-Saharan Africa). </p><p></p><p class="bulletIndent1">Factors that increase morbidity also increase mortality and are described in detail above. </p><p></p><p class="headingAnchor" id="H31294123"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The clinical presentation after unsafe abortion may mimic that of safe abortion and pregnancy loss (miscarriage); however, providers generally do <strong>not</strong> need to differentiate between these entities to care for the patient [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/d/html/5442.html" rel="external">"Pregnancy loss (miscarriage): Clinical presentations, diagnosis, and initial evaluation", section on 'Clinical presentations'</a>.)</p><p>Such patients may present to several different types of facilities (eg, emergency department, outpatient clinic) and have a variety of presentations. Some patients present to confirm their abortion is complete, while others present because of complications they are unable to manage at home. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemorrhage</strong> – Hemorrhage is the most common presentation after unsafe abortion and may present with symptoms suggestive of heavy blood loss (eg, feeling dizzy, faint, having loss of consciousness). Diaphoresis, pallor, dyspnea, tachycardia, hypotension, and orthostasis are often late signs of hemorrhage, especially in young healthy patients. (See  <a class="medical medical_review" href="/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Hemorrhage'</a>.)</p><p></p><p class="bulletIndent1">Vaginal bleeding is often present in patients with retained products of conception (RPOC) or those with vaginal, cervical, and uterine lacerations from trauma (eg, insertion of a foreign body into the vagina and/or uterus). By contrast, intraabdominal bleeding is more common in patients with uterine perforation, abdominal trauma, or lacerations that occur laterally (particularly near vessels in the parametrial space). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – Infection may present with abdominal and/or pelvic pain, malodorous vaginal discharge, fever and chills, vaginal bleeding or spotting, or uterine or adnexal tenderness. Infection may also present as sepsis, septic shock, organ failure, and disseminated intravascular coagulation. (See  <a class="medical medical_review" href="/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Infection/retained products of conception'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trauma/Injury</strong> – Abortion-related trauma (eg, insertion of a foreign body into the vagina and/or uterus, direct abdominal trauma) may result in injuries to the genital tract, including vaginal and cervical lacerations, uterine perforation, and chemical burns. Patients with lacerations or uterine perforation may present with hemorrhage or symptoms and signs of infection. Patients who have used or been administered local (ie, vaginal) toxic substances may present with chemical burns to the vagina. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug toxicity</strong> – Patients may present with symptoms and signs (eg, physiologic excitation and/or depression) of drug toxicity. (See  <a class="medical medical_review" href="/d/html/324.html" rel="external">"General approach to drug poisoning in adults", section on 'Physical examination'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Herbal preparations</strong> – Multiorgan failure has been observed in patients that ingest certain herbs such as ruda, Carachipita, arnica, and bardana. Hepatoxicity may occur with ingestion of pennyroyal or black cohosh  (<a class="graphic graphic_table graphicRef76400" href="/d/graphic/76400.html" rel="external">table 1</a>). Pulmonary aspiration with chemical pneumonitis may occur with ingestion of turpentine. Death has been observed in patients that ingest ruda or Carachipita [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/3618.html" rel="external">"Hepatotoxicity due to herbal medications and dietary supplements", section on 'Specific hepatotoxic herbs'</a> and  <a class="medical medical_review" href="/d/html/6489.html" rel="external">"Acute hydrocarbon exposure: Clinical toxicity, evaluation, and diagnosis", section on 'Hydrocarbon ingestion'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">Misoprostol</a> – While misoprostol is overall a very safe medication, cases of poor misoprostol drug quality and toxicity at very high doses (eg, 3 to 8.5 mg) have been reported [<a href="#rid26">26-30</a>]. For comparison, the standard dose for medication abortion is 800 mcg, and cumulative doses of up to 2.2 mg administered over a period of 12 hours have been described with no serious adverse effects [<a href="#rid31">31</a>]. </p><p></p><p class="bulletIndent2">Manifestations of <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> toxicity may include high fever, shaking chills, abdominal cramping, vomiting, diarrhea, tremor, agitation, confusion, rhabdomyolysis, hypoxemia, and hypotension [<a href="#rid28">28-30,32</a>]. Symptoms develop soon after ingestion, as misoprostol is rapidly absorbed (it is completely absorbed from the stomach 1.5 hours after ingestion). One case of a pregnant adolescent was reported who experienced stomach and distal esophagus necrosis, upper gastrointestinal bleeding, sepsis, multiorgan failure, and ultimately death after ingesting 12 mg of misoprostol orally [<a href="#rid33">33</a>].</p><p></p><p class="headingAnchor" id="H3913790685"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H2891914007"><span class="h2">History</span><span class="headingEndMark"> — </span>A focused history is obtained, including date of last menstrual period, risk factors for ectopic pregnancy  (<a class="graphic graphic_table graphicRef82282" href="/d/graphic/82282.html" rel="external">table 2</a>), and (for patients who disclose their pregnancy) if an intrauterine pregnancy has been confirmed previously. However, many patients will not disclose their pregnancy or unsafe abortion procedure, even in settings where abortion is legal [<a href="#rid34">34</a>]. Thus, clinicians should always consider the possibility of pregnancy during the initial medical assessment of a reproductive-age patients with a uterus. </p><p>It is important to initially limit questions to those that are necessary for evaluation and treatment of an unsafe abortion. For example, a clinician can chart that a patient is pregnant and is bleeding, without specifying if the pregnancy was desired [<a href="#rid35">35</a>]. In the United States, clinicians are <strong>not</strong> required to report an abortion to law enforcement authorities and disclosure may violate Health Insurance Portability and Accountability Act (HIPPA) privacy rules [<a href="#rid36">36,37</a>]. It is important to note that Black, Hispanic, and low-income individuals are more likely than White or high-income individuals to be targeted by the criminal justice system [<a href="#rid38">38,39</a>]. </p><p class="headingAnchor" id="H3653226462"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Hemodynamic stability is assessed and those with life-threatening hemorrhage and/or infection are identified. Physical examination should also assess for findings consistent with drug toxicity (eg, gastrointestinal distress, hyperthermia, tachycardia) [<a href="#rid40">40</a>]. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/324.html" rel="external">"General approach to drug poisoning in adults", section on 'Physical examination'</a>.)</p><p>A complete pelvic examination is performed, although this may be deferred in unstable patients until after stabilization (eg, with vascular access and blood product replacement). Speculum examination is used to assess for cervical dilation, blood clot or tissue in the cervical os or vagina, active bleeding from the cervical os, sanguinopurulent and/or malodourous discharge, and vaginal or cervical lacerations. Bimanual pelvic examination is used to assess for cervical motion tenderness, deep vaginal lacerations, adnexal and/or abdominal tenderness, adnexal masses, and uterine enlargement, tenderness, and tone. A tender and/or boggy uterus is concerning for infection or retained products of conception (RPOC); cervical dilation and uterine enlargement may also be present with RPOC. By contrast, a vaginal or cervical laceration, or uterine perforation, should be suspected in the setting of heavy vaginal bleeding with firm uterine tone.</p><p class="headingAnchor" id="H1096672485"><span class="h2">Laboratories</span><span class="headingEndMark"> — </span>Laboratory studies may include the following: complete blood count; Rh blood type and crossmatching (for patients with heavy bleeding); quantitative beta human chorionic gonadotropin (hCG; if an intrauterine pregnancy has not been confirmed); comprehensive metabolic panel; lactate (if there is concern for sepsis or injury to the adjacent viscera [ie, bladder, bowel]); and toxicology screen (if there is concern for intentional or unintentional poisoning). (See  <a class="medical medical_review" href="/d/html/5487.html" rel="external">"Ectopic pregnancy: Clinical manifestations and diagnosis", section on 'Human chorionic gonadotropin'</a> and  <a class="medical medical_review" href="/d/html/324.html" rel="external">"General approach to drug poisoning in adults", section on 'Diagnosis of poisoning'</a>.)</p><p>Rh testing, with administration of Rhogam to Rh negative individuals, is generally not needed for patients at early gestational ages (eg, &lt;8 to &lt;12 weeks). This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Alloimmunization prevention'</a>.)</p><p class="headingAnchor" id="H2359071507"><span class="h2">Imaging studies</span><span class="headingEndMark"> — </span>Transvaginal ultrasound (by a clinician with expertise in gynecologic ultrasound) is the preferred initial imaging study in patients presenting with unsafe abortion. Ultrasound can evaluate for RPOC, ongoing intrauterine pregnancy, ectopic pregnancy, adnexal masses, hematometra, and intrabdominal bleeding. </p><p>However, for hemodynamically unstable patients, a bedside transabdominal ultrasound may be used to quickly assess for intraperitoneal hemorrhage. </p><p class="headingAnchor" id="H2841109152"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H3039225790"><span class="h2">Hemorrhage</span><span class="headingEndMark"> — </span>Initial management of patients with hemorrhage includes vascular access and blood product replacement. Intravenous fluids may be given to hypotensive patients but are generally avoided in patients with hemorrhage given the increased risk of coagulopathy from dilution of clotting factors and platelets. If disseminated intravascular coagulopathy (DIC) is suspected, treatment may also include administration of clotting factors and platelets. These are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/113837.html" rel="external">"Initial management of moderate to severe hemorrhage in the adult trauma patient"</a> and  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Treatment'</a>.)</p><p>For patients with hemorrhage in whom the suspicion for retained products is low:</p><p class="bulletIndent1"><span class="glyph">●</span>Initial management includes uterine massage, administration of a uterotonic agent (eg, <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> 400 mcg sublingually; <a class="drug drug_general" data-topicid="9637" href="/d/drug information/9637.html" rel="external">methylergonovine</a> 0.2 mg intramuscularly [IM]; carboprost 0.25 mg IM every 15 to 90 minutes, as needed, to a total cumulative dose of 2 mg [eight doses]), an intrauterine pack, and/or an intrauterine balloon. (See  <a class="medical medical_review" href="/d/html/6714.html" rel="external">"Postpartum hemorrhage: Medical and minimally invasive management", section on 'Administer additional uterotonic medications'</a> and  <a class="medical medical_review" href="/d/html/4440.html" rel="external">"Postpartum hemorrhage: Use of an intrauterine hemorrhage-control device"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subsequent management for hemodynamically unstable patients or in patients in whom bleeding is unable to be controlled with conservative measures, includes uterine artery embolization or hysterectomy. (See  <a class="medical medical_review" href="/d/html/6714.html" rel="external">"Postpartum hemorrhage: Medical and minimally invasive management", section on 'Consider uterine or hypogastric artery embolization'</a> and  <a class="medical medical_review" href="/d/html/6712.html" rel="external">"Postpartum hemorrhage: Management approaches requiring laparotomy", section on 'Role of hysterectomy'</a>.)</p><p></p><p>Management of patients with hemorrhage and suspected RPOC or hemorrhage due to trauma are described below. (See <a class="local">'Retained products of conception'</a> below and <a class="local">'Trauma/injuries'</a> below.)</p><p class="headingAnchor" id="H57597847"><span class="h2">Infection</span><span class="headingEndMark"> — </span>Infection from unsafe abortion may be caused by RPOC, trauma, or nonsterile techniques and can result in sepsis, septic shock, organ failure, DIC, and future sterility. </p><p>Infection is usually due to Enterobacteriaceae, streptococci, staphylococci, and enterococci. Mixed infections, anaerobic organisms, and fungi also occur. </p><p>Management of such patients includes immediate initiation of broad-spectrum antibiotics and surgical evacuation of the uterus; this is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/130878.html" rel="external">"Septic abortion: Clinical presentation and management", section on 'Management'</a>.)</p><p class="headingAnchor" id="H1495534889"><span class="h2">Trauma/injuries</span></p><p class="headingAnchor" id="H220105706"><span class="h3">Lacerations</span><span class="headingEndMark"> — </span>Lower genital tract lacerations generally require surgical repair. Pressure (with a finger, sponge stick, or damp gauze pack) may be applied to sites of active bleeding while waiting for a gynecologist or other surgeon.</p><p>For patients with lacerations extending into the peritoneal cavity, laparotomy or laparoscopy may be needed to assess for other intra-abdominal trauma and for repair. (See  <a class="medical medical_review" href="/d/html/5449.html" rel="external">"Evaluation and management of female lower genital tract trauma"</a>.)</p><p class="headingAnchor" id="H2061439966"><span class="h3">Uterine perforation</span><span class="headingEndMark"> — </span>For patients with suspected uterine perforation, there is a low threshold for surgical exploration, as uterine perforation cannot be confirmed or excluded with any imaging study, and it is often difficult to ascertain if there is injury to surrounding structures. In hemodynamically stable patients, laparoscopy may allow for initial assessment of intra-abdominal trauma and laparotomy may be avoided if bleeding is controlled and bowel, bladder, and blood vessels are intact. Laparotomy is generally needed for hemodynamically unstable patients or in whom there is a high suspicion for intra-abdominal organ injury. (See  <a class="medical medical_review" href="/d/html/3309.html" rel="external">"Uterine perforation during gynecologic procedures", section on 'Management'</a>.)</p><p class="headingAnchor" id="H2194030330"><span class="h3">Chemical burns</span><span class="headingEndMark"> — </span>For patients with chemical burns, the type and potency of the toxic agent and duration of contact primarily determine the degree of tissue destruction. As with drug toxicity, management of chemical burns can be complex, and we recommend clinicians consult with a medical toxicologist or poison control center about specific exposures. This is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/345.html" rel="external">"Topical chemical burns: Initial evaluation and management"</a> and <a class="local">'Drug toxicity'</a> below.)</p><p class="headingAnchor" id="H450672993"><span class="h2">Retained products of conception</span><span class="headingEndMark"> — </span>For hemodynamically unstable patients with hemorrhage and suspected RPOC, either based on clinical or ultrasound findings, uterine evacuation is performed with dilation and curettage or evacuation. For hemodynamically stable patients with vaginal bleeding and suspected RPOC, options include expectant management, medical management (eg, <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>), or surgical evacuation of the uterus. How to choose between treatment options, as well as their detailed descriptions, are described separately. If intrauterine instrumentation is performed, antibiotic prophylaxis is administered. (See  <a class="medical medical_review" href="/d/html/5482.html" rel="external">"Retained products of conception in the first half of pregnancy", section on 'Management'</a>.) </p><p>Not all patients with suspected RPOC require management. For asymptomatic patients in whom ultrasound examination demonstrates a thickened endometrium or enhanced myometrial vascularity (EMV), treatment may not be needed [<a href="#rid41">41</a>]. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5482.html" rel="external">"Retained products of conception in the first half of pregnancy", section on 'Asymptomatic patients with suspected RPOC'</a>.)</p><p class="headingAnchor" id="H1687952547"><span class="h2">Drug toxicity</span><span class="headingEndMark"> — </span>Management of drug toxicity is generally supportive as patients may not know or disclose which medications or herbs they ingested. However, some patients may be critically ill and require life-saving treatments. (See  <a class="medical medical_review" href="/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a> and  <a class="medical medical_review" href="/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose"</a>.)</p><p>For patients with <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> toxicity (eg, hyperthermia, tachycardia, metabolic acidosis, rhabdomyolysis), treatment includes removing any remaining tablets from the vagina or cheeks and supportive care until symptoms resolve, which takes approximately 12 hours [<a href="#rid28">28,30,32,40,42</a>]. If more expedient removal is needed and the misoprostol was taken orally or buccally, activated charcoal may be used, but misoprostol is completely absorbed from the stomach 1.5 hours after ingestion, so this is often not helpful. It is not known if misoprostol acid is dialyzable. However, because misoprostol is metabolized like a fatty acid, it is unlikely that dialysis would be appropriate treatment for overdosage [<a href="#rid43">43</a>]. Treatment of rhabdomyolysis is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a> and  <a class="medical medical_review" href="/d/html/14036.html" rel="external">"Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)"</a>.)</p><p>For patients with <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> toxicity (rare), treatment may also include gastrointestinal decontamination [<a href="#rid40">40</a>]. As mifepristone has antiglucocorticoid activity, it can precipitate acute adrenal insufficiency or crisis, and steroid administration may be required in some patients. </p><p>Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical and/or medical toxicologists available for bedside consultation and/or inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H31293484"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>The prevention of unsafe abortion requires a multifaceted approach including [<a href="#rid44">44-47</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Expanded access to safe abortion. Historically, liberalization of abortion laws has resulted in increased access to safe abortion. In Romania, the 1989 repeal of laws banning contraception and abortion was associated with a 50 percent decrease in maternal mortality within one year [<a href="#rid48">48</a>]. In the United States, the number of abortion-related deaths fell after Roe v. Wade in 1973: from almost 40 per million live births in 1970 to 8 per million live births in 1976, in part due to the increased availability of legal abortion [<a href="#rid49">49</a>]. With increased restrictions in the United States and the overturn of Roe v. Wade in 2022, this rate is expected to increase again [<a href="#rid8">8</a>]. In contrast to the time before Roe v. Wade, safe self-managed abortion (SMA) using self-procured <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> and <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> may be a key component in ensuring safety. (See  <a class="medical medical_review" href="/d/html/3296.html" rel="external">"First-trimester pregnancy termination: Medication abortion", section on 'Self-managed'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prevention of unintended pregnancy. This can be done by maintaining (or increasing) access to contraceptive services. </p><p></p><p class="bulletIndent1">Victims of intimate partner violence are also at risk for unintended pregnancy and abortion, as well as other health consequences. A study by the World Health Organization (WHO) estimated that reducing intimate partner violence by 50 percent could potentially reduce unintended pregnancy by 2 to 18 percent and abortion by 4.5 to 40 percent, according to population-attributable risk estimates [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Provision of high-quality postabortion medical care. Postabortion care is critical for reducing morbidity and mortality given early recognition and management of complications. Patients can also be offered contraception counseling at that time. (See  <a class="medical medical_review" href="/d/html/109209.html" rel="external">"Contraception: Postabortion"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduction of restrictive abortion policies and stigma. Abortion is least safe where it is most restricted. In countries where abortion is highly restricted, only 25 percent of abortions are safe; by contrast, in countries where abortion is unrestricted, 87 percent of abortions are safe [<a href="#rid4">4</a>].</p><p></p><p class="headingAnchor" id="H4194545650"><span class="h1">OTHER HEALTH CONSEQUENCES OF ABORTION RESTRICTION</span><span class="headingEndMark"> — </span>In addition to unsafe abortion, abortion restriction may lead to other health consequences. Such consequences may include [<a href="#rid51">51-54</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Delays in treatment for patients with ectopic pregnancy or septic abortion [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limitations in treatment options for patients with obstetric (eg, fetal anomalies, previability preterm prelabor rupture of membranes [PPROM] or chorioamnionitis, early onset pre-eclampsia with severe features) or other medical (eg, patients with cancer) conditions [<a href="#rid56">56-60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limited access to emergency contraception.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limited access to <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> or <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> for treatment of other medical conditions (eg, rheumatoid arthritis, pregnancy loss).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased hesitancy to prescribe teratogenic agents (eg, <a class="drug drug_general" data-topicid="8582" href="/d/drug information/8582.html" rel="external">isotretinoin</a>, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>) for treatment of other medical conditions (eg, moderate to severe acne vulgaris, focal or generalized seizures, bipolar disorder) [<a href="#rid61">61,62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limited access to assisted reproductive technology procedures (eg, in vitro fertilization [IVF]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increasing requests for permanent sterilization procedures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increasing rates of economic insecurity (eg, food and housing insecurity, loss of employment) [<a href="#rid63">63,64</a>] and children placed into foster care [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increasing rates of domestic violence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exacerbation of pre-existing, or new onset of, mental health disorders [<a href="#rid62">62,66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increasing rates of suicide. In a longitudinal study including data from the US Centers for Disease Control and Prevention (CDC) between 1974 and 2016, increased enforcement of laws restricting access to abortion was associated with more than a fivefold increase in suicide rates among females ages 20 to 34 years (coefficient of interest 0.17, 95% CI 0.03-0.32) [<a href="#rid67">67</a>]. By contrast, rates of suicide are <strong>not</strong> increased in patients who undergo pregnancy termination. (See  <a class="medical medical_review" href="/d/html/14193.html" rel="external">"Pregnancy termination and potential psychiatric outcomes", section on 'Suicide'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased rates of maternal and infant mortality [<a href="#rid68">68</a>]. </p><p></p><p>A registry has been established to better understand how clinical care has changed since Roe v. Wade was overturned; information about this registry is available <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcarepostroe.ucsf.edu%2F&amp;token=KiuSOBbJZdCKw4iyuuWyU0H74B%2BcG7tHJ%2B0Nlp4Kb2W4eE4QHh18vWK%2BUvP0iAGW&amp;TOPIC_ID=14192" target="_blank">online</a>.</p><p class="headingAnchor" id="H973415740"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109182.html" rel="external">"Society guideline links: Pregnancy termination"</a>.)</p><p class="headingAnchor" id="H18736556"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Unsafe abortion is defined by the Society of Family Planning (SFP) as an abortion performed by an unskilled or untrained provider using unsafe (eg, ingesting toxic substances, abdominal trauma, intrauterine instrumentation) or less-studied (eg, herbal preparations, botanicals) methods to terminate a pregnancy. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methods of unsafe abortion</strong> – The four major methods of unsafe abortion are (see <a class="local">'Methods of unsafe abortion'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral and injectable treatments (eg, metal salts, phosphorus, lead, kerosene, turpentine, detergent solutions, <a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">chloroquine</a>, hormones, and numerous teas and herbal remedies).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preparations placed in the cervix, vagina, or rectum (eg, potassium permanganate tablets, herbal preparations, enemas).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Instrumentation of the uterus (eg, catheter insertion followed by infusion of alcohol, <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, or other solution; insertion of foreign bodies).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Trauma to the abdomen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Morbidity and mortality</strong> – The most common complications from unsafe abortion include hemorrhage, anemia, infection, and trauma (eg, uterine perforation, vaginal and cervical lacerations, chemical burns). Complications may lead to death or other long-term sequelae (eg, infertility). (See <a class="local">'Morbidity and mortality'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presentation</strong> – Patients undergoing unsafe abortion may present to several different types of facilities, have a variety of presentations, and may disclose neither their pregnancy nor unsafe abortion procedure, even in settings where abortion is legal. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Management includes stabilization of the patient, followed by treatment of the underlying complication (eg, hemorrhage, infection, injury). (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hemorrhage</strong> – For patients with hemorrhage and in whom no retained products of conception (RPOC) are suspected, initial management includes uterine massage, administration of uterotonic agents (eg, <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>, <a class="drug drug_general" data-topicid="9637" href="/d/drug information/9637.html" rel="external">methylergonovine</a>, carboprost), an intrauterine pack, and/or an intrauterine balloon. Subsequent management for hemodynamically unstable patients or in patients in whom bleeding is unable to be controlled with conservative measures, includes uterine artery embolization or hysterectomy. (See <a class="local">'Hemorrhage'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>RPOC</strong> – For hemodynamically unstable patients with hemorrhage and suspected RPOC, uterine evacuation is performed with dilation and curettage or evacuation. For hemodynamically stable patients with vaginal bleeding and suspected RPOC, options include expectant management, medical management (eg, <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>), or surgical evacuation of the uterus. For asymptomatic patients in whom ultrasound examination demonstrates a thickened endometrium or enhanced myometrial vascularity, treatment may not be needed. (See <a class="local">'Retained products of conception'</a> above and  <a class="medical medical_review" href="/d/html/5482.html" rel="external">"Retained products of conception in the first half of pregnancy", section on 'Management'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Drug toxicity</strong> – Management of drug toxicity is generally supportive. While <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> is considered a very safe medication, cases of poor drug quality and toxicity at very high doses have been reported. Treatment of such patients involves removing any remaining tablets from the vagina or stomach and supportive care until symptoms resolve, which takes approximately 12 hours. (See <a class="local">'Drug toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – The prevention of unsafe abortion requires a multifaceted approach including expanded access to safe abortion, prevention of unintended pregnancy, provision of high-quality postabortion medical care, and reduction of the stigma associated with abortion. (See <a class="local">'Prevention'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fawcus SR. Maternal mortality and unsafe abortion. Best Pract Res Clin Obstet Gynaecol 2008; 22:533.</a></li><li class="breakAll">Society of Family Planning interim clinical recommendations: Self-managed abortion. Society of Family Planning. Available at: https://www.societyfp.org/society-of-family-planning-interim-clinical-recommendations-self-managed-abortion/ (Accessed on July 18, 2022).</li><li><a class="nounderline abstract_t">Hessini L, Brookman-Amissah E, Crane BB. Global policy change and women's access to safe abortion: the impact of the World Health Organization's guidance in Africa. Afr J Reprod Health 2006; 10:14.</a></li><li><a class="nounderline abstract_t">Ganatra B, Gerdts C, Rossier C, et al. Global, regional, and subregional classification of abortions by safety, 2010-14: estimates from a Bayesian hierarchical model. Lancet 2017; 390:2372.</a></li><li><a class="nounderline abstract_t">Sundaram A, Juarez F, Bankole A, Singh S. Factors associated with abortion-seeking and obtaining a safe abortion in Ghana. Stud Fam Plann 2012; 43:273.</a></li><li><a class="nounderline abstract_t">Jones RK. How commonly do US abortion patients report attempts to self-induce? Am J Obstet Gynecol 2011; 204:23.e1.</a></li><li><a class="nounderline abstract_t">Grimes DA, Benson J, Singh S, et al. Unsafe abortion: the preventable pandemic. Lancet 2006; 368:1908.</a></li><li><a class="nounderline abstract_t">Grossman D, Perritt J, Grady D. The Impending Crisis of Access to Safe Abortion Care in the US. JAMA Intern Med 2022; 182:793.</a></li><li class="breakAll">Sharing Responsibility: Women, Society &amp; Abortion Worldwide, The Alan Guttmacher Institute, New York 1999.</li><li><a class="nounderline abstract_t">Bury L, Aliaga Bruch S, Machicao Barbery X, Garcia Pimentel F. Hidden realities: What women do when they want to terminate an unwanted pregnancy in Bolivia. Int J Gynaecol Obstet 2012; 118 Suppl 1:S4.</a></li><li><a class="nounderline abstract_t">Ruha AM, Babu K, Carey J, et al. Criminalization of Abortion Will Lead to Increased Poisoning Illness and Deaths. J Med Toxicol 2022; 18:185.</a></li><li><a class="nounderline abstract_t">Feng C, Fay KE, Burns MM. Toxicities of herbal abortifacients. Am J Emerg Med 2023; 68:42.</a></li><li><a class="nounderline abstract_t">Harris LH, Grossman D. Complications of Unsafe and Self-Managed Abortion. N Engl J Med 2020; 382:1029.</a></li><li><a class="nounderline abstract_t">Grossman D, Holt K, Peña M, et al. Self-induction of abortion among women in the United States. Reprod Health Matters 2010; 18:136.</a></li><li><a class="nounderline abstract_t">Burnhill MS. Treatment of women who have undergone chemically induced abortions. J Reprod Med 1985; 30:610.</a></li><li><a class="nounderline abstract_t">Ugboma HA, Akani CI. Abdominal massage: another cause of maternal mortality. Niger J Med 2004; 13:259.</a></li><li><a class="nounderline abstract_t">Raifman S, Ralph L, Biggs MA, Grossman D. "I'll just deal with this on my own": a qualitative exploration of experiences with self-managed abortion in the United States. Reprod Health 2021; 18:91.</a></li><li><a class="nounderline abstract_t">Singh S. Hospital admissions resulting from unsafe abortion: estimates from 13 developing countries. Lancet 2006; 368:1887.</a></li><li><a class="nounderline abstract_t">Singh S, Maddow-Zimet I. Facility-based treatment for medical complications resulting from unsafe pregnancy termination in the developing world, 2012: a review of evidence from 26 countries. BJOG 2016; 123:1489.</a></li><li><a class="nounderline abstract_t">Adler AJ, Filippi V, Thomas SL, Ronsmans C. Quantifying the global burden of morbidity due to unsafe abortion: magnitude in hospital-based studies and methodological issues. Int J Gynaecol Obstet 2012; 118 Suppl 2:S65.</a></li><li><a class="nounderline abstract_t">Costa SH. Commercial availability of misoprostol and induced abortion in Brazil. Int J Gynaecol Obstet 1998; 63 Suppl 1:S131.</a></li><li><a class="nounderline abstract_t">Gerdts C, Vohra D, Ahern J. Measuring unsafe abortion-related mortality: a systematic review of the existing methods. PLoS One 2013; 8:e53346.</a></li><li class="breakAll">World Health Organization (WHO). Preventing unsafe abortion. https://www.who.int/news-room/fact-sheets/detail/preventing-unsafe-abortion.</li><li><a class="nounderline abstract_t">Grossman D, Baum SE, Andjelic D, et al. A harm-reduction model of abortion counseling about misoprostol use in Peru with telephone and in-person follow-up: A cohort study. PLoS One 2018; 13:e0189195.</a></li><li><a class="nounderline abstract_t">Ciganda C, Laborde A. Herbal infusions used for induced abortion. J Toxicol Clin Toxicol 2003; 41:235.</a></li><li><a class="nounderline abstract_t">Prada E, Singh S, Villarreal C. Health consequences of unsafe abortion in Colombia, 1989-2008. Int J Gynaecol Obstet 2012; 118 Suppl 2:S92.</a></li><li><a class="nounderline abstract_t">Hyman A, Blanchard K, Coeytaux F, et al. Misoprostol in women's hands: a harm reduction strategy for unsafe abortion. Contraception 2013; 87:128.</a></li><li><a class="nounderline abstract_t">Austin J, Ford MD, Rouse A, Hanna E. Acute intravaginal misoprostol toxicity with fetal demise. J Emerg Med 1997; 15:61.</a></li><li><a class="nounderline abstract_t">Bentov Y, Sheiner E, Katz M. Misoprostol overdose during the first trimester of pregnancy. Eur J Obstet Gynecol Reprod Biol 2004; 115:108.</a></li><li><a class="nounderline abstract_t">Barros JG, Reis I, Graça LM. Acute misoprostol toxicity during the first trimester of pregnancy. Int J Gynaecol Obstet 2011; 113:157.</a></li><li><a class="nounderline abstract_t">el-Refaey H, Templeton A. Induction of abortion in the second trimester by a combination of misoprostol and mifepristone: a randomized comparison between two misoprostol regimens. Hum Reprod 1995; 10:475.</a></li><li><a class="nounderline abstract_t">Bond GR, Van Zee A. Overdosage of misoprostol in pregnancy. Am J Obstet Gynecol 1994; 171:561.</a></li><li><a class="nounderline abstract_t">Henriques A, Lourenço AV, Ribeirinho A, et al. Maternal death related to misoprostol overdose. Obstet Gynecol 2007; 109:489.</a></li><li><a class="nounderline abstract_t">Harris LH. Stigma and abortion complications in the United States. Obstet Gynecol 2012; 120:1472.</a></li><li class="breakAll">Society of Family Planning interim clinical recommendations: Self-managed
abortion. Society of Family Planning. Available at: https://www.societyfp.org/wp-content/uploads/2022/06/SFP-Interim-Recommendation-Self-managed-abortion-07.14.22.pdf</li><li class="breakAll">HIPAA Privacy Rule and Disclosures of Information Relating to Reproductive Health Care. US Department of Health and Human Services. Available at: https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/phi-reproductive-health/index.html (Accessed on July 25, 2022).</li><li><a class="nounderline abstract_t">Watson K, Paul M, Yanow S, Baruch J. Supporting, Not Reporting - Emergency Department Ethics in a Post-Roe Era. N Engl J Med 2022; 387:861.</a></li><li><a class="nounderline abstract_t">Grossman D, Verma N. Self-managed Abortion in the US. JAMA 2022; 328:1693.</a></li><li><a class="nounderline abstract_t">Kheyfets A, Miller B, Amutah-Onukagha N. Implications for racial inequities in maternal health if Roe v Wade is lost. Lancet 2022; 400:9.</a></li><li><a class="nounderline abstract_t">Mazer-Amirshahi M, Ye P. Toxicity of abortifacients: A review for physicians in the post roe era. Am J Emerg Med 2022; 61:7.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists. Practice bulletin no. 143: medical management of first-trimester abortion. Obstet Gynecol 2014; 123:676.</a></li><li><a class="nounderline abstract_t">Graber DJ, Meier KH. Acute misoprostol toxicity. Ann Emerg Med 1991; 20:549.</a></li><li class="breakAll">CYTOTEC Overdosage. Pfizer. Available at: https://www.pfizermedicalinformation.com/en-us/cytotec/overdose (Accessed on July 18, 2022).</li><li><a class="nounderline abstract_t">Faúndes A, Comendant R, Dilbaz B, et al. Preventing unsafe abortion: Achievements and challenges of a global FIGO initiative. Best Pract Res Clin Obstet Gynaecol 2020; 62:101.</a></li><li><a class="nounderline abstract_t">Faúndes A. Strategies for the prevention of unsafe abortion. Int J Gynaecol Obstet 2012; 119 Suppl 1:S68.</a></li><li class="breakAll">International Federation of Gynecology and Obstetrics, International Confederation of Midwives, International Council of Nurses, United States Agency for International Development. FIGO Consensus Statement. Family planning: a key component of post abortion care. October 8, 2009. http://www.figo.org/news/figo-consensus-statementfamily- planning-key-component-post-abortion-care (Accessed on February 18, 2014).</li><li class="breakAll">International Federation of Gynecology and Obstetrics. Consensus statement on uterine evacuation. Uterine evacuation: use vacuum aspiration or medications, not sharp curettage. July 12, 2011. http://www.figo.org/news/new-downloaduterineevacuation-figo-consensus-statement-003824 (Accessed on February 18, 2014).</li><li><a class="nounderline abstract_t">Stephenson P, Wagner M, Badea M, Serbanescu F. Commentary: the public health consequences of restricted induced abortion--lessons from Romania. Am J Public Health 1992; 82:1328.</a></li><li><a class="nounderline abstract_t">Cates W Jr, Rochat RW, Grimes DA, Tyler CW Jr. Legalized abortion: effect on national trends of maternal and abortion-related mortality (1940 through 1976). Am J Obstet Gynecol 1978; 132:211.</a></li><li><a class="nounderline abstract_t">Pallitto CC, García-Moreno C, Jansen HA, et al. Intimate partner violence, abortion, and unintended pregnancy: results from the WHO Multi-country Study on Women's Health and Domestic Violence. Int J Gynaecol Obstet 2013; 120:3.</a></li><li><a class="nounderline abstract_t">Harris LH. Navigating Loss of Abortion Services - A Large Academic Medical Center Prepares for the Overturn of Roe v. Wade. N Engl J Med 2022; 386:2061.</a></li><li><a class="nounderline abstract_t">Paltrow LM, Harris LH, Marshall MF. Beyond Abortion: The Consequences of Overturning Roe. Am J Bioeth 2022; 22:3.</a></li><li><a class="nounderline abstract_t">Ralph LJ, Schwarz EB, Grossman D, Foster DG. Self-reported Physical Health of Women Who Did and Did Not Terminate Pregnancy After Seeking Abortion Services: A Cohort Study. Ann Intern Med 2019; 171:238.</a></li><li><a class="nounderline abstract_t">Reingold RB, Gostin LO, Goodwin MB. Legal Risks and Ethical Dilemmas for Clinicians in the Aftermath of Dobbs. JAMA 2022; 328:1695.</a></li><li><a class="nounderline abstract_t">MacDonald A, Gershengorn HB, Ashana DC. The Challenge of Emergency Abortion Care Following the Dobbs Ruling. JAMA 2022; 328:1691.</a></li><li><a class="nounderline abstract_t">Shuman AG, Aapro MS, Anderson B, et al. Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization. Oncologist 2022.</a></li><li><a class="nounderline abstract_t">Suran M. Treating Cancer in Pregnant Patients After Roe v Wade Overturned. JAMA 2022; 328:1674.</a></li><li><a class="nounderline abstract_t">Nambiar A, Patel S, Santiago-Munoz P, et al. Maternal morbidity and fetal outcomes among pregnant women at 22 weeks' gestation or less with complications in 2 Texas hospitals after legislation on abortion. Am J Obstet Gynecol 2022; 227:648.</a></li><li><a class="nounderline abstract_t">Raymond MB, Barbera JP, Boudova S, et al. Implications for Prenatal Genetic Testing in the United States After the Reversal of Roe v Wade. Obstet Gynecol 2023; 141:445.</a></li><li><a class="nounderline abstract_t">Miller HE, Fraz F, Zhang J, et al. Abortion Bans and Resource Utilization for Congenital Heart Disease: A Decision Analysis. Obstet Gynecol 2023; 142:652.</a></li><li><a class="nounderline abstract_t">Rubin R. Threats to Evidence-Based Care With Teratogenic Medications in States With Abortion Restrictions. JAMA 2022; 328:1671.</a></li><li><a class="nounderline abstract_t">Wisner KL, Appelbaum PS. Abortion Restriction and Mental Health. JAMA Psychiatry 2023; 80:285.</a></li><li><a class="nounderline abstract_t">Foster DG, Biggs MA, Ralph L, et al. Socioeconomic Outcomes of Women Who Receive and Women Who Are Denied Wanted Abortions in the United States. Am J Public Health 2018; 108:407.</a></li><li class="breakAll">Miller S, Wherry LR, Foster DG. The Economic Consequences of Being Denied an Abortion. NBER Working Paper No. 26662, National Bureau of Economic Research, 2020.</li><li><a class="nounderline abstract_t">Adkins S, Talmor N, White MH, et al. Association Between Restricted Abortion Access and Child Entries Into the Foster Care System. JAMA Pediatr 2024; 178:37.</a></li><li><a class="nounderline abstract_t">Thornburg B, Kennedy-Hendricks A, Rosen JD, Eisenberg MD. Anxiety and Depression Symptoms After the Dobbs Abortion Decision. JAMA 2024; 331:294.</a></li><li><a class="nounderline abstract_t">Zandberg J, Waller R, Visoki E, Barzilay R. Association Between State-Level Access to Reproductive Care and Suicide Rates Among Women of Reproductive Age in the United States. JAMA Psychiatry 2023; 80:127.</a></li><li><a class="nounderline abstract_t">Harper LM, Leach JM, Robbins L, et al. All-Cause Mortality in Reproductive-Aged Females by State: An Analysis of the Effects of Abortion Legislation. Obstet Gynecol 2023; 141:236.</a></li></ol></div><div id="topicVersionRevision">Topic 14192 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18249585" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Maternal mortality and unsafe abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18249585" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Maternal mortality and unsafe abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17518128" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Global policy change and women's access to safe abortion: the impact of the World Health Organization's guidance in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28964589" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Global, regional, and subregional classification of abortions by safety, 2010-14: estimates from a Bayesian hierarchical model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23239247" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Factors associated with abortion-seeking and obtaining a safe abortion in Ghana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20863478" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : How commonly do US abortion patients report attempts to self-induce?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17126724" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Unsafe abortion: the preventable pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35737374" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The Impending Crisis of Access to Safe Abortion Care in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35737374" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The Impending Crisis of Access to Safe Abortion Care in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22840269" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hidden realities: What women do when they want to terminate an unwanted pregnancy in Bolivia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35612783" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Criminalization of Abortion Will Lead to Increased Poisoning Illness and Deaths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36924751" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Toxicities of herbal abortifacients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32160664" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Complications of Unsafe and Self-Managed Abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21111358" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Self-induction of abortion among women in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4045835" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment of women who have undergone chemically induced abortions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15532228" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Abdominal massage: another cause of maternal mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33947413" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : "I'll just deal with this on my own": a qualitative exploration of experiences with self-managed abortion in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17126721" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hospital admissions resulting from unsafe abortion: estimates from 13 developing countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26287503" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Facility-based treatment for medical complications resulting from unsafe pregnancy termination in the developing world, 2012: a review of evidence from 26 countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22920625" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Quantifying the global burden of morbidity due to unsafe abortion: magnitude in hospital-based studies and methodological issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10075223" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Commercial availability of misoprostol and induced abortion in Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23341939" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Measuring unsafe abortion-related mortality: a systematic review of the existing methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23341939" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Measuring unsafe abortion-related mortality: a systematic review of the existing methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29320513" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A harm-reduction model of abortion counseling about misoprostol use in Peru with telephone and in-person follow-up: A cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12807304" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Herbal infusions used for induced abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22920628" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Health consequences of unsafe abortion in Colombia, 1989-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23228504" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Misoprostol in women's hands: a harm reduction strategy for unsafe abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9017489" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Acute intravaginal misoprostol toxicity with fetal demise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15223178" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Misoprostol overdose during the first trimester of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21333990" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Acute misoprostol toxicity during the first trimester of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7769082" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Induction of abortion in the second trimester by a combination of misoprostol and mifepristone: a randomized comparison between two misoprostol regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8059844" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Overdosage of misoprostol in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17267868" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Maternal death related to misoprostol overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23168775" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Stigma and abortion complications in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23168775" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Stigma and abortion complications in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23168775" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Stigma and abortion complications in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36053234" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Supporting, Not Reporting - Emergency Department Ethics in a Post-Roe Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36318121" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Self-managed Abortion in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35659035" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Implications for racial inequities in maternal health if Roe v Wade is lost.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36007432" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Toxicity of abortifacients: A review for physicians in the post roe era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24553166" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Practice bulletin no. 143: medical management of first-trimester abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1902633" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Acute misoprostol toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1902633" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Acute misoprostol toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31331743" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Preventing unsafe abortion: Achievements and challenges of a global FIGO initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22883917" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Strategies for the prevention of unsafe abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22883917" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Strategies for the prevention of unsafe abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22883917" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Strategies for the prevention of unsafe abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1415854" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Commentary: the public health consequences of restricted induced abortion--lessons from Romania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/686111" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Legalized abortion: effect on national trends of maternal and abortion-related mortality (1940 through 1976).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22959631" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Intimate partner violence, abortion, and unintended pregnancy: results from the WHO Multi-country Study on Women's Health and Domestic Violence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35544368" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Navigating Loss of Abortion Services - A Large Academic Medical Center Prepares for the Overturn of Roe v. Wade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35652910" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Beyond Abortion: The Consequences of Overturning Roe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31181576" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Self-reported Physical Health of Women Who Did and Did Not Terminate Pregnancy After Seeking Abortion Services: A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36318123" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Legal Risks and Ethical Dilemmas for Clinicians in the Aftermath of Dobbs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36318126" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The Challenge of Emergency Abortion Care Following the Dobbs Ruling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35962750" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36173620" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Treating Cancer in Pregnant Patients After Roe v Wade Overturned.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35803323" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Maternal morbidity and fetal outcomes among pregnant women at 22 weeks' gestation or less with complications in 2 Texas hospitals after legislation on abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36649348" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Implications for Prenatal Genetic Testing in the United States After the Reversal of Roe v Wade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37535962" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Abortion Bans and Resource Utilization for Congenital Heart Disease: A Decision Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36223128" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Threats to Evidence-Based Care With Teratogenic Medications in States With Abortion Restrictions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36753289" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Abortion Restriction and Mental Health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29345993" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Socioeconomic Outcomes of Women Who Receive and Women Who Are Denied Wanted Abortions in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29345993" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Socioeconomic Outcomes of Women Who Receive and Women Who Are Denied Wanted Abortions in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37930718" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Association Between Restricted Abortion Access and Child Entries Into the Foster Care System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38261045" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Anxiety and Depression Symptoms After the Dobbs Abortion Decision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36576746" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Association Between State-Level Access to Reproductive Care and Suicide Rates Among Women of Reproductive Age in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36318777" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : All-Cause Mortality in Reproductive-Aged Females by State: An Analysis of the Effects of Abortion Legislation.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
